Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
RAD's Cash-to-Debt is ranked lower than
95% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.51 vs. RAD: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
RAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.03 Max: 0.27
Current: 0.03
0
0.27
Equity-to-Asset 0.06
RAD's Equity-to-Asset is ranked lower than
96% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. RAD: 0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
RAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.38  Med: 0.06 Max: 0.57
Current: 0.06
-0.38
0.57
Debt-to-Equity 9.74
RAD's Debt-to-Equity is ranked lower than
98% of the 301 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.52 vs. RAD: 9.74 )
Ranked among companies with meaningful Debt-to-Equity only.
RAD' s Debt-to-Equity Range Over the Past 10 Years
Min: -470.18  Med: 0.87 Max: 421.85
Current: 9.74
-470.18
421.85
Debt-to-EBITDA 5.93
RAD's Debt-to-EBITDA is ranked lower than
82% of the 296 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.38 vs. RAD: 5.93 )
Ranked among companies with meaningful Debt-to-EBITDA only.
RAD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.96  Med: 6.71 Max: 12.26
Current: 5.93
-3.96
12.26
Interest Coverage 0.80
RAD's Interest Coverage is ranked lower than
97% of the 331 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.52 vs. RAD: 0.80 )
Ranked among companies with meaningful Interest Coverage only.
RAD' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 1.23 Max: 2.22
Current: 0.8
0.02
2.22
Piotroski F-Score: 6
Altman Z-Score: 2.68
Beneish M-Score: -2.77
WACC vs ROIC
4.06%
1.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 1.11
RAD's Operating Margin % is ranked lower than
75% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. RAD: 1.11 )
Ranked among companies with meaningful Operating Margin % only.
RAD' s Operating Margin % Range Over the Past 10 Years
Min: -7.81  Med: 1.23 Max: 3.32
Current: 1.11
-7.81
3.32
Net Margin % 0.28
RAD's Net Margin % is ranked lower than
78% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.98 vs. RAD: 0.28 )
Ranked among companies with meaningful Net Margin % only.
RAD' s Net Margin % Range Over the Past 10 Years
Min: -11.09  Med: -0.7 Max: 7.95
Current: 0.28
-11.09
7.95
ROE % 14.07
RAD's ROE % is ranked higher than
70% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.10 vs. RAD: 14.07 )
Ranked among companies with meaningful ROE % only.
RAD' s ROE % Range Over the Past 10 Years
Min: -1148.43  Med: -32.62 Max: 51.83
Current: 14.07
-1148.43
51.83
ROA % 0.77
RAD's ROA % is ranked lower than
76% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.68 vs. RAD: 0.77 )
Ranked among companies with meaningful ROA % only.
RAD' s ROA % Range Over the Past 10 Years
Min: -29.43  Med: -2.45 Max: 26.83
Current: 0.77
-29.43
26.83
ROC (Joel Greenblatt) % 15.81
RAD's ROC (Joel Greenblatt) % is ranked higher than
55% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.54 vs. RAD: 15.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -44.02  Med: 8.35 Max: 22.13
Current: 15.81
-44.02
22.13
3-Year Revenue Growth Rate 5.90
RAD's 3-Year Revenue Growth Rate is ranked higher than
60% of the 346 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.90 vs. RAD: 5.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16  Med: 1.8 Max: 19.6
Current: 5.9
-16
19.6
3-Year EBITDA Growth Rate -3.50
RAD's 3-Year EBITDA Growth Rate is ranked lower than
71% of the 317 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.50 vs. RAD: -3.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -84.8  Med: 2.1 Max: 43.8
Current: -3.5
-84.8
43.8
3-Year EPS without NRI Growth Rate -74.10
RAD's 3-Year EPS without NRI Growth Rate is ranked lower than
99% of the 286 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.70 vs. RAD: -74.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.1  Med: 6.1 Max: 479.9
Current: -74.1
-74.1
479.9
GuruFocus has detected 4 Warning Signs with Rite Aid Corp RAD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RAD's 30-Y Financials

Financials (Next Earnings Date: 2017-12-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

RAD Guru Trades in Q3 2016

Eric Mindich 3,078,000 sh (New)
Paul Singer 3,179,854 sh (New)
Jeremy Grantham 3,889,139 sh (+63.23%)
Pioneer Investments 1,326,427 sh (+44.20%)
Leucadia National 1,208,291 sh (+40.83%)
David Einhorn 13,443,035 sh (+30.14%)
Paul Singer 2,000,000 sh (unchged)
Paul Tudor Jones 122,800 sh (unchged)
John Paulson Sold Out
Jim Simons Sold Out
John Burbank Sold Out
Mario Gabelli 1,369,975 sh (-1.15%)
Paul Tudor Jones 52,162 sh (-37.61%)
» More
Q4 2016

RAD Guru Trades in Q4 2016

First Pacific Advisors 169,000 sh (New)
David Einhorn 20,462,962 sh (+52.22%)
Paul Tudor Jones 122,800 sh (unchged)
Eric Mindich Sold Out
Paul Tudor Jones Sold Out
Paul Singer Sold Out
Leucadia National Sold Out
Pioneer Investments 1,294,187 sh (-2.43%)
Mario Gabelli 1,191,650 sh (-13.02%)
Jeremy Grantham 2,047,600 sh (-47.35%)
» More
Q1 2017

RAD Guru Trades in Q1 2017

Leucadia National 102,100 sh (New)
Jeremy Grantham 3,565,000 sh (+74.11%)
Mario Gabelli 1,228,344 sh (+3.08%)
Paul Singer 3,424,600 sh (unchged)
First Pacific Advisors Sold Out
David Einhorn 16,778,989 sh (-18.00%)
Pioneer Investments 740,142 sh (-42.81%)
» More
Q2 2017

RAD Guru Trades in Q2 2017

Steven Cohen 1,000,000 sh (New)
Paul Singer 2,739,600 sh (unchged)
David Einhorn 16,778,989 sh (unchged)
Pioneer Investments Sold Out
Leucadia National Sold Out
Jeremy Grantham Sold Out
Mario Gabelli 1,008,068 sh (-17.93%)
» More
» Details

Insider Trades

Latest Guru Trades with RAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Reduce -17.93%0.01%$2.89 - $4.75 $ 1.82-52%1,008,068
Leucadia National 2017-06-30 Sold Out 0.04%$2.89 - $4.75 $ 1.82-52%0
David Einhorn 2017-03-31 Reduce -18.00%0.52%$4.25 - $8.7 $ 1.82-70%16,778,989
Mario Gabelli 2017-03-31 Add 3.08%$4.25 - $8.7 $ 1.82-70%1,228,344
Leucadia National 2017-03-31 New Buy0.04%$4.25 - $8.7 $ 1.82-70%102,100
David Einhorn 2016-12-31 Add 52.22%0.99%$6.43 - $8.61 $ 1.82-76%20,462,962
Mario Gabelli 2016-12-31 Reduce -13.02%0.01%$6.43 - $8.61 $ 1.82-76%1,191,650
Leucadia National 2016-12-31 Sold Out 0.76%$6.43 - $8.61 $ 1.82-76%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Rite Aid Corp

SymbolPriceYieldDescription
RADCO0.000.00Conv Pfd Shs Series -I-

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare:TSE:9627, SSE:2928, JSE:CLS, SHSE:603883, SHSE:603939, JSE:DCP, TSE:3549, TSE:3148, SZSE:002727, TSE:7649, TSE:3098, TSX:PJC.A, SZSE:002462, TSE:3088, MEX:FRAGUA B, HKSE:08138, MIC:PRTK, TSE:3141, NAS:PETS, OHEL:OKDBV » details
Traded in other countries:RTA.Germany,
Headquarter Location:USA
Rite Aid Corp operates retail drugstore chains in the United States. The business activity of the group is functioned through two segments namely Retail Pharmacy and Pharmacy Services. It operates more than 4,500 stores in 31 states across the country.

Rite Aid is a large retail drugstore chain in the United States. The company reports via two segments: retail pharmacy and pharmacy services. The retail pharmacy segment generates revenue primarily through the sale of prescription drugs, along with an assortment of merchandise that includes over-the-counter medications, health and beauty aids, personal-care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other everyday consumables. The pharmacy-services segment relates to EnvisionRx, a fully owned subsidiary that operates as a pharmacy benefit management provider offering a broad range of pharmaceutical services.

Guru Investment Theses on Rite Aid Corp

Mario Gabelli Comments on Rite Aid Corp. - Aug 15, 2017

Rite Aid Corp. (0.3%)(RAD – $2.95 –NYSE)(NYSE:RAD) is a Camp Hill, Pennsylvania based retail drugstore chain. The company originally entered into a $17.2 billion merger with Walgreens Boots Alliance Inc, another international pharmacy operator, during October of 2015. The deal was marked by a lengthy and complex regulatory review which lengthened the timeline past its January 30, 2017 termination date. At that point, the deal was subsequently extended to June 30, 2017 and the price revised to $14.2 billion. Approaching this second termination date and due to opposition by the Federal Trade Commission, the parties restructured the deal to an asset sale whereby Walgreens Boots Alliance will acquire 2,186 Rite Aid Corp. stores across the country for a price of $5.175 billion and the payment of a $325 million termination fee associated with the original deal. The asset sale is expected to face a simpler antitrust approval process and reach its conclusion by the end of the year.



From Mario Gabelli (Trades, Portfolio)'s second quarter 2017 Gabelli ABC Fund commentary.

Check out Mario Gabelli latest stock trades

David Einhorn Comments on Rite Aid - May 17, 2017

RAD (NYSE:RAD) fell from $8.24 to $4.25. We had expected that Walgreens and RAD would satisfy regulatory concerns and close the merger at $9 per share. Instead, the deal was re-cut to between $6.50 and $ 7.00, and even at this date, the regulatory concerns are not resolved. We are watching the situation carefully and we have trimmed the position, as our original thinking was incorrect.





  • From Einhorn's first-quarter 2017 shareholder commentary.


Check out David Einhorn latest stock trades

Top Ranked Articles about Rite Aid Corp

Strategic Research Analysis ­ Positioning to Benefit on  Abbott, Rite Aid, Kroger, Celgene, Twitter, and NIKE ­ Effects of Key Drivers of Growth and Emerging Market Trends
Should you buy Centurylink, General Motors, JD.com, Marathon Petroleum Corporation, or Rite Aid Stock?
Rite Aid Plummets on Weak Quarterly Sales, Revenue Following failed takeover, FTC approved the sale of 1,932 stores to Walgreens last week
Drugstore chain Rite Aid Corp. (NYSE:RAD) reported its second-quarter 2018 results before the opening bell on Sept. 28. Read more...
Core-Mark Announces Supply Chain Contract Renewal with Rite Aid
Stock Reports for Advanced Micro Devices, Alibaba, Hasbro, Michael Kors and Rite Aid
Mario Gabelli Comments on Rite Aid Corp. Guru stock highlight
Rite Aid Corp. (0.3%)(RAD – $2.95 –NYSE)(NYSE:RAD) is a Camp Hill, Pennsylvania based retail drugstore chain. The company originally entered into a $17.2 billion merger with Walgreens Boots Alliance Inc, another international pharmacy operator, during October of 2015. The deal was marked by a lengthy and complex regulatory review which lengthened the timeline past its January 30, 2017 termination date. At that point, the deal was subsequently extended to June 30, 2017 and the price revised to $14.2 billion. Approaching this second termination date and due to opposition by the Federal Trade Commission, the parties restructured the deal to an asset sale whereby Walgreens Boots Alliance will acquire 2,186 Rite Aid Corp. stores across the country for a price of $5.175 billion and the payment of a $325 million termination fee associated with the original deal. The asset sale is expected to face a simpler antitrust approval process and reach its conclusion by the end of the year. Read more...
Health Dialog Introduces New Medication Therapy Management Services
Stocks That Fell to 3-Year Lows in the Week of June 9 BT Group PLC (BT), Mallinckrodt PLC (MNK), Rite Aid Corp (RAD), and Frontier Communications Corp (FTR) have declined to their respective three-year lows.
BT Group PLC (NYSE:BT), Mallinckrodt PLC (NYSE:MNK), Rite Aid Corp (NYSE:RAD), and Frontier Communications Corp (NASDAQ:FTR) have declined to their three-year lows. Read more...
Health Dialog Provides Nurse Line Services to Kern Health Systems' Population Health Program
David Einhorn Comments on Rite Aid Guru stock highlight
RAD (NYSE:RAD) fell from $8.24 to $4.25. We had expected that Walgreens and RAD would satisfy regulatory concerns and close the merger at $9 per share. Instead, the deal was re-cut to between $6.50 and $ 7.00, and even at this date, the regulatory concerns are not resolved. We are watching the situation carefully and we have trimmed the position, as our original thinking was incorrect. Read more...

Ratios

vs
industry
vs
history
PE Ratio 22.75
RAD's PE Ratio is ranked lower than
65% of the 305 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.33 vs. RAD: 22.75 )
Ranked among companies with meaningful PE Ratio only.
RAD' s PE Ratio Range Over the Past 10 Years
Min: 2.39  Med: 19.5 Max: 328.5
Current: 22.75
2.39
328.5
PE Ratio without NRI 22.75
RAD's PE Ratio without NRI is ranked lower than
63% of the 307 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.07 vs. RAD: 22.75 )
Ranked among companies with meaningful PE Ratio without NRI only.
RAD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.39  Med: 19.59 Max: 219
Current: 22.75
2.39
219
Price-to-Owner-Earnings 67.40
RAD's Price-to-Owner-Earnings is ranked lower than
85% of the 216 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.15 vs. RAD: 67.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
RAD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.2  Med: 16.06 Max: 547.5
Current: 67.4
3.2
547.5
PB Ratio 2.62
RAD's PB Ratio is ranked lower than
65% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.85 vs. RAD: 2.62 )
Ranked among companies with meaningful PB Ratio only.
RAD' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 4.29 Max: 151.55
Current: 2.62
0.29
151.55
PS Ratio 0.06
RAD's PS Ratio is ranked higher than
96% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. RAD: 0.06 )
Ranked among companies with meaningful PS Ratio only.
RAD' s PS Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.08 Max: 0.34
Current: 0.06
0.01
0.34
Price-to-Free-Cash-Flow 13.37
RAD's Price-to-Free-Cash-Flow is ranked higher than
62% of the 159 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.63 vs. RAD: 13.37 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RAD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.88  Med: 19.78 Max: 567.5
Current: 13.37
1.88
567.5
Price-to-Operating-Cash-Flow 3.82
RAD's Price-to-Operating-Cash-Flow is ranked higher than
83% of the 198 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.46 vs. RAD: 3.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RAD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.53  Med: 8.39 Max: 94.42
Current: 3.82
0.53
94.42
EV-to-EBIT 13.74
RAD's EV-to-EBIT is ranked higher than
58% of the 316 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.23 vs. RAD: 13.74 )
Ranked among companies with meaningful EV-to-EBIT only.
RAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -2331.6  Med: 22.4 Max: 3761.3
Current: 13.74
-2331.6
3761.3
EV-to-EBITDA 7.36
RAD's EV-to-EBITDA is ranked higher than
78% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.89 vs. RAD: 7.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
RAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: 12.4 Max: 17.3
Current: 7.36
-6.2
17.3
EV-to-Revenue 0.27
RAD's EV-to-Revenue is ranked higher than
75% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.60 vs. RAD: 0.27 )
Ranked among companies with meaningful EV-to-Revenue only.
RAD' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 0.3 Max: 0.6
Current: 0.27
0.2
0.6
PEG Ratio 2.83
RAD's PEG Ratio is ranked lower than
63% of the 182 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.14 vs. RAD: 2.83 )
Ranked among companies with meaningful PEG Ratio only.
RAD' s PEG Ratio Range Over the Past 10 Years
Min: 0.16  Med: 2.64 Max: 9.61
Current: 2.83
0.16
9.61
Current Ratio 1.74
RAD's Current Ratio is ranked higher than
73% of the 358 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.18 vs. RAD: 1.74 )
Ranked among companies with meaningful Current Ratio only.
RAD' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.86 Max: 4.73
Current: 1.74
0.81
4.73
Quick Ratio 0.77
RAD's Quick Ratio is ranked higher than
53% of the 358 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.74 vs. RAD: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
RAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 0.52 Max: 1.25
Current: 0.77
0.13
1.25
Days Inventory 42.40
RAD's Days Inventory is ranked lower than
55% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.32 vs. RAD: 42.40 )
Ranked among companies with meaningful Days Inventory only.
RAD' s Days Inventory Range Over the Past 10 Years
Min: 40.29  Med: 62.34 Max: 70.58
Current: 42.4
40.29
70.58
Days Sales Outstanding 20.97
RAD's Days Sales Outstanding is ranked lower than
60% of the 281 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.08 vs. RAD: 20.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
RAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.31  Med: 13.58 Max: 20.97
Current: 20.97
7.31
20.97
Days Payable 25.06
RAD's Days Payable is ranked lower than
78% of the 273 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 42.45 vs. RAD: 25.06 )
Ranked among companies with meaningful Days Payable only.
RAD' s Days Payable Range Over the Past 10 Years
Min: 21.83  Med: 25.18 Max: 29.42
Current: 25.06
21.83
29.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
RAD's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 220 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.60 vs. RAD: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -2.7 Max: 1.5
Current: -2.7
-25.8
1.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.92
RAD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
69% of the 225 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.39 vs. RAD: 0.92 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RAD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.88  Med: 2.82 Max: 30.35
Current: 0.92
0.88
30.35
Price-to-Median-PS-Value 0.75
RAD's Price-to-Median-PS-Value is ranked higher than
80% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. RAD: 0.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 2.75 Max: 11.43
Current: 0.75
0.11
11.43
Earnings Yield (Greenblatt) % 7.26
RAD's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.84 vs. RAD: 7.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34  Med: 3.7 Max: 8.2
Current: 7.26
-34
8.2
Forward Rate of Return (Yacktman) % 12.04
RAD's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 252 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.34 vs. RAD: 12.04 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RAD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -32.8  Med: 0.5 Max: 38
Current: 12.04
-32.8
38

More Statistics

Revenue (TTM) (Mil) $32,091.44
EPS (TTM) $ 0.08
Beta1.59
Short Percentage of Float13.34%
52-Week Range $1.63 - 8.77
Shares Outstanding (Mil)1,063.96

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}